Targeting MET amplification in EGFR-mutant non-small-cell lung cancer

Affiliations

¹ Laboratory of Cellular and Molecular Biology, Institute for Health Science Research Germans Trias I Pujol (IGTP), Badalona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: rrosell@iconcologia.net.
² Laboratory of Cellular and Molecular Biology, Institute for Health Science Research Germans Trias I Pujol (IGTP), Badalona, Spain.
³ Medical Oncology Unit, AOU Policlinico G Martino, Department of Human Pathology, University of Messina, Messina, Italy.

Comment

Rafael Rosell et al. Lancet Respir Med. 2020 Nov.

. 2020 Nov;8(11):1068-1070.

doi: 10.1016/S2213-2600(20)30171-5. Epub 2020 May 29.

¹ Laboratory of Cellular and Molecular Biology, Institute for Health Science Research Germans Trias I Pujol (IGTP), Badalona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: rrosell@iconcologia.net.
² Laboratory of Cellular and Molecular Biology, Institute for Health Science Research Germans Trias I Pujol (IGTP), Badalona, Spain.
³ Medical Oncology Unit, AOU Policlinico G Martino, Department of Human Pathology, University of Messina, Messina, Italy.

No abstract available

Comment on

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC; INSIGHT Investigators. Wu YL, et al. Lancet Respir Med. 2020 Nov;8(11):1132-1143. doi: 10.1016/S2213-2600(20)30154-5. Epub 2020 May 29. Lancet Respir Med. 2020. PMID: 32479794 Clinical Trial.